Story perspectives

FDA panel backs Galleri benefits over risks for 50+

By Drooid · Sep 24, 2026, 2:10 PM UTC · How we work

Summary

FDA Panel Backs Galleri

The FDA Molecular and Clinical Genetics Panel voted Galleri’s benefits outweigh its risks for adults 50+.
Panel members affirmed safety unanimously (10-0) and split on effectiveness 6-4.
Members voted 7-2, with one abstention, that benefits outweigh risks.
GRAIL’s shares rose ~35%, valuing the company at $4.85 billion.
FDA will issue a final decision on Galleri by early 2027.

Summary

Medicare Considers Reimbursement

Galleri is currently sold directly to consumers who pay out-of-pocket.
Approval would allow Medicare and private insurers to reimburse Galleri, expanding patient access.
Panelist Victor van Berkel emphasized adding Galleri to, not replacing, existing cancer-screening protocols.
The FDA may consider the panel’s advice.
The agency is not legally required to adopt the recommendations.

Summary

Advocates Warn Delays

Consumer advocates warn patients may delay care after a negative Galleri result, risking fatal outcomes.
FDA reviewers note the test is less accurate at detecting early-stage cancers, where treatment benefits are greatest.
Johns Hopkins scientist Nickolas Papadopoulos says doctors must explain pros and cons before patients undergo Galleri testing.
The test’s list price of $949 may limit access for many, despite potential Medicare coverage after approval.

1 of 3

FDA Panel Backs Galleri

The FDA Molecular and Clinical Genetics Panel voted Galleri’s benefits outweigh its risks for adults 50+.
Panel members affirmed safety unanimously (10-0) and split on effectiveness 6-4.
Members voted 7-2, with one abstention, that benefits outweigh risks.
GRAIL’s shares rose ~35%, valuing the company at $4.85 billion.
FDA will issue a final decision on Galleri by early 2027.

1 / 3